The present invention relates to compounds having the general formula
##STR00001## or a pharmaceutically acceptable salt thereof, wherein
R.sup.1 is a saturated or unsaturated 5-, 6- or 7-membered, ring
containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring
may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo
groups, and wherein R.sup.1 is additionally substituted; and R.sup.2 is a
substituted C.sub.1-6alkyl. Also included is a method of prophylaxis or
treatment of inflammation, rheumatoid arthritis, Pagets disease,
osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous
leukemia, pancreatic .beta. cell destruction, osteoarthritis, rheumatoid
spondylitis, gouty arthritis, inflammatory bowel disease, adult
respiratory distress syndrome (ARDS), psoriasis, Crohn's disease,
allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis,
asthma, muscle degeneration, cachexia, Reiter's syndrome, type I
diabetes, type II diabetes, bone resorption diseases, graft vs. host
reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia
reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis,
cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever,
myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza,
adenovirus, the herpes viruses or herpes zoster infection in a mammal
comprising administering an effective amount a compound as described
above.